Core Viewpoint - The Hong Kong stock market saw a net inflow of 611 million HKD from Northbound trading on December 23, with significant buying in stocks like Alibaba and Meituan, while major sell-offs occurred in China Mobile and Tencent. Group 1: Northbound Trading Summary - Northbound trading recorded a net buy of 611 million HKD, with Shanghai Stock Connect showing a net sell of 582 million HKD and Shenzhen Stock Connect showing a net buy of 1.193 billion HKD [1] - The most bought stocks included Alibaba-W (09988), Meituan-W (03690), and Zijin Mining (02899) [1] - The most sold stocks included China Mobile (00941), Tencent (00700), and SMIC (00981) [1] Group 2: Stock-Specific Details - Alibaba-W (09988) had a net inflow of 1.359 billion HKD, driven by the launch of the AI DingTalk operating system [5] - Meituan-W (03690) received a net buy of 223 million HKD [7] - Zijin Mining (02899) saw a net buy of 111 million HKD, with Macquarie raising its target price by 75% to 40 HKD [5] - Tencent (00700) faced a net sell of 1.088 billion HKD [7] - China Mobile (00941) experienced a net sell of 1.975 billion HKD [7] - SMIC (00981) had a net sell of 141 million HKD, influenced by U.S. export regulations on AI chips [6]

Core Viewpoint - The Hong Kong stock market experienced a net inflow of 611 million HKD from northbound trading on December 23, with significant buying in Alibaba, Meituan, and Zijin Mining, while China Mobile, Tencent, and SMIC saw the most selling [1][6]. Group 1: Northbound Trading Activity - Northbound trading recorded a net buy of 611 million HKD, with Shanghai Stock Connect showing a net sell of 582 million HKD and Shenzhen Stock Connect showing a net buy of 1.193 billion HKD [1]. - The most bought stocks included Alibaba-W (09988), Meituan-W (03690), and Zijin Mining (02899) [1]. - The most sold stocks included China Mobile (00941), Tencent (00700), and SMIC (00981) [1]. Group 2: Stock-Specific Details - Alibaba-W (09988) had a net buy of 13.67 billion HKD, driven by the launch of the AI DingTalk operating system [2][6]. - Meituan-W (03690) received a net buy of 2.23 billion HKD [8]. - Zijin Mining (02899) saw a net buy of 1.11 billion HKD, with an upgraded production forecast for its copper project [6]. - China Mobile (00941) faced a net sell of 14.82 billion HKD [2]. - Tencent (00700) experienced a net sell of 7.78 billion HKD [2]. - SMIC (00981) had a net sell of 6.29 billion HKD, influenced by U.S. export regulations on AI chips [7].

Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) has risen over 4%, currently trading at HKD 8.59 with a transaction volume of HKD 443 million, following significant insider buying and the approval of a new drug for clinical trials [1] Group 1: Stock Performance - CSPC Pharmaceutical Group's stock increased by 4.12% to HKD 8.59 [1] - The trading volume reached HKD 443 million [1] Group 2: Insider Activity - Chairman and Executive Director Cai Dongchen purchased 13.454 million shares at HKD 8.1957 each, totaling approximately HKD 110 million [1] - Post-purchase, the total number of shares held by Cai is about 2.91 billion, representing a 25.26% ownership stake [1] Group 3: Product Development - CSPC has received approval from the National Medical Products Administration of China for its self-developed SYH2085 tablet to conduct clinical trials [1] - SYH2085 is a novel oral small molecule candidate aimed at inhibiting the RNA polymerase acidic protein (PA) endonuclease activity of the influenza virus, targeting treatment for adults and adolescents aged 12 and above with uncomplicated influenza A and B [1] - This product is expected to be an effective treatment for influenza, enhancing the company's product pipeline in the field of anti-infective therapies [1]

Group 1 - The core viewpoint of the article highlights the significant increase in the stock price of CSPC Pharmaceutical Group, which rose over 4% to HKD 8.59, with a trading volume of HKD 443 million [1] - The chairman and executive director, Cai Dongchen, increased his stake in CSPC Pharmaceutical by acquiring 13.454 million shares at a price of HKD 8.1957 per share, totaling approximately HKD 110 million. After this purchase, his total shareholding reached about 2.91 billion shares, representing a 25.26% ownership stake [1] - CSPC Pharmaceutical announced that its developed drug SYH2085 has received approval from the National Medical Products Administration of China to conduct clinical trials. This innovative drug is designed to inhibit the RNA polymerase acidic protein (PA) endonuclease activity of the influenza virus and is intended for treating uncomplicated influenza in adults and adolescents aged 12 and above [1] Group 2 - The approval of SYH2085 for clinical trials is expected to enhance the company's product pipeline in the field of anti-infective treatments, indicating a high clinical development value for the drug [1]

Group 1 - The core point of the article is that CSPC Pharmaceutical Group (01093.HK) has received approval from the National Medical Products Administration of China to conduct clinical trials for its self-developed drug SYH2085 [1] - SYH2085 is a novel oral small molecule candidate drug designed to inhibit the RNA polymerase acidic protein (PA) endonuclease activity of the influenza virus, targeting both influenza A and B viruses [1] - The clinical indication approved is for the treatment of uncomplicated influenza in adults and adolescents aged 12 and above, with preclinical studies showing significant antiviral effects and favorable pharmacokinetic properties [1] Group 2 - The approval of SYH2085 is expected to enhance the company's product pipeline in the field of anti-infective treatments, indicating high clinical development value [1] - Additionally, CSPC Pharmaceutical Group announced the appointment of Cai Lei as Vice Chairman and Executive Director [2]

Core Viewpoint - The approval of SYH2085 by the National Medical Products Administration of China marks a significant advancement for the company in the development of innovative antiviral treatments for influenza [1] Group 1: Product Development - SYH2085 is a novel oral small molecule candidate drug developed by the company, designed to inhibit the RNA polymerase acidic protein (PA) endonuclease activity of influenza viruses [1] - The clinical indication approved is for the treatment of uncomplicated influenza A and B in adults and adolescents aged 12 and older [1] Group 2: Clinical Research and Efficacy - Preclinical studies have demonstrated that SYH2085 exhibits clear, broad-spectrum, and excellent inhibitory effects against both influenza A and B viruses [1] - The drug has shown effectiveness in reducing viral load and flu-like symptoms in animal models, along with favorable pharmacokinetic properties and safety [1] Group 3: Market Potential - The approval of SYH2085 is expected to enhance the company's product pipeline in the field of anti-infective treatments, indicating high clinical development value [1]

Core Viewpoint - The approval of SYH2085 by the National Medical Products Administration of China marks a significant advancement for the company in the development of innovative antiviral treatments for influenza [1] Group 1: Product Development - SYH2085 is a novel oral small molecule candidate drug developed by the company, designed to inhibit the RNA polymerase acidic protein (PA) endonuclease activity of influenza viruses [1] - The clinical indication approved is for the treatment of uncomplicated influenza A and B in adults and adolescents aged 12 and older [1] - Preclinical studies have demonstrated that SYH2085 exhibits clear, broad-spectrum, and excellent inhibitory effects against both influenza A and B viruses, effectively reducing viral load and flu-like symptoms in animal models [1] Group 2: Clinical and Market Potential - The drug shows promising pharmacokinetic properties and safety, indicating a high clinical development value [1] - The introduction of SYH2085 is expected to enhance the company's product pipeline in the field of anti-infective treatments [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 自願公告 SYH2085片在中國獲臨床試驗批准 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 布 ， 本 集 團 開 發 的 SYH2085 片（「 該 產 品 」）已 獲 得 中 華 人 民 共 和 國 國 家 藥 品 監 督 管 理 局 批 准，可在中國開展臨床試驗。 該 產 品 為 本 集 團 自主 研 發 的 化 學 1 類創 新 藥 ， 是 一 款 可 抑 制 流 感 病 毒的 RNA 聚 合 酶 酸 性 蛋 白(PA)核酸內切酶活性的新型口服小分子候選藥物。本次獲批的臨床適應症為用於治療成 人及12歲以上青少年單純性甲型和乙型流感。臨床 ...